The Tissue, Pathology and Bioinformatics Core A of the Moffitt Skin SPORE will be a multifunctional core devoted to the (1) optimal procurement, handling, processing, and pathologic characterization of tissues from patients with melanoma and non-melanoma skin cancer, as well as the (2) accurate compilation, storage, and analysis of clinical, pathologic, and investigational data generated from the Skin SPORE projects. The ultimate goals of Core A are to utilize pathology and informatics expertise and resources to both support the translation of hypotheses generated by the basic science-driven projects into accurate, clinically relevant conclusions that can be generalized to the prevention and/or treatment of melanoma and non-melanoma skin cancer, and to carry out and/or support the translational assays that are included within the trials of this Skin SPORE. Core A will take advantage of and supplement institutional shared resources for tissue and blood procurement, banking, nucleic acid isolation, and histopathology services including immunohistochemstry and tissue microarray production, as well as analytic microscopy facilities for digital imaging and analysis. Pathologic review, grading, and classification of all patient tissue specimens will be conducted by Core A. Institutional information technology resources will provide researchers a centralized location to store data, access analytical tools, in a seamless application environment managed by the Core. These facilities will be leveraged by the co-leaders, who will oversee and manage acquisition, storage, and distribution of all tissues and data derived in the course of the projects.
The Tissue, Pathology and Bioinformatics Core A of the Moffitt Skin SPORE will conduct the collection and storage of frozen tissue for lab-based translational studies (Projects 1, 2, and 3) as well as fixed tissue for molecular analyses and immunohistochemical staining/evaluation of molecular targets of interest (Projects 1, 2, 3, and 4). Core A will collect serum, hair follicle, and skin swabs for assessment of HPV and MCV infection (Project 4). The Core will storage and manage all data derived from these projects. The Core will also oversee the distribution of archived, clinically annotated biospecimens to support the Developmental Research and Career Development projects of the SPORE.
|Strom, Tobin; Harrison, Louis B; Giuliano, Anna R et al. (2017) Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer 84:304-314|
|Faião-Flores, F; Alves-Fernandes, D K; Pennacchi, P C et al. (2017) Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells. Oncogene 36:1849-1861|
|Zhu, Genyuan; Falahat, Rana; Wang, Kui et al. (2017) Tumor-Associated Tertiary Lymphoid Structures: Gene-Expression Profiling and Their Bioengineering. Front Immunol 8:767|
|Wan, Lixin; Chen, Ming; Cao, Juxiang et al. (2017) The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. Cancer Discov 7:424-441|
|Markowitz, Joseph; Wang, Jiang; Vangundy, Zach et al. (2017) Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Sci Rep 7:15424|
|Yagawa, Yohsuke; Robertson-Tessi, Mark; Zhou, Susan L et al. (2017) Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy. Sci Rep 7:15996|
|Li, Jiannong; Smalley, Inna; Schell, Michael J et al. (2017) SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer. Bioinformatics 33:2951-2953|
|Niessner, Heike; Sinnberg, Tobias; Kosnopfel, Corinna et al. (2017) BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. Clin Cancer Res 23:6203-6214|
|Wang, Daniel Y; Eroglu, Zeynep; Ozgun, Alpaslan et al. (2017) Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol Res 5:357-362|
|Robinson, James P; Rebecca, Vito W; Kircher, David A et al. (2017) Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res 27:545-557|
Showing the most recent 10 out of 47 publications